Science
Featuring an interview with Dr Kristen Ciombor, including the following topics: Final overall survival from the Phase III KN177 study evaluating pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (mCRC) (0:00) Trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing mCRC: Final results from the DESTINY-CRC01 study (1:54) My Pathway HER2 basket study: Pertuzumab with trastuzumab for patients with HER2-positive advanced solid tumors in a large, tissue-agnostic cohort (3:49) Nivolumab with ipilimumab or nivolumab with chemotherapy versus chemotherapy alone as first-line treatment for advanced esophageal squamous cell carcinoma: First results from the CheckMate 648 study (6:38) First-line nivolumab with chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma: Expanded efficacy and safety data from the CheckMate 649 study (8:15) Adjuvant nivolumab for resected esophageal or GEJ cancer after neoadjuvant chemoradiation therapy: Expanded efficacy and safety analyses from the CheckMate 577 study (9:57) Trastuzumab deruxtecan in patients with HER2-positive advanced gastric or GEJ adenocarcinoma: Final overall survival results from the Phase II DESTINY-Gastric01 study (11:10) Pembrolizumab with trastuzumab and chemotherapy for HER2-positive metastatic gastric or GEJ cancer: Initial findings of the Phase III KEYNOTE-811 study (12:27) FIGHT: A Phase II study of bemarituzumab combined with modified FOLFOX6 as first-line therapy for FGFR2b-positive advanced gastric or GEJ adenocarcinoma (15:24) IMbrave150 trial: Exploratory analysis of the association between treatment response and overall survival among patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab/bevacizumab compared to sorafenib (16:19) Updated results of a Phase Ib study of regorafenib with pembrolizumab for first-line treatment of advanced HCC (17:36) Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Update of the FIGHT-202 study (18:39) NIFTY: A Phase II study of liposomal irinotecan in combination with fluorouracil and leucovorin for patients with metastatic biliary tract cancer after disease progression on gemcitabine/cisplatin (20:14) Preoperative chemoradiation therapy to improve overall survival for patients with pancreatic cancer: Long-term results of the Phase III PREOPANC trial (21:40) Efficacy and safety of zenocutuzumab in patients with advanced pancreatic cancer and other solid tumors harboring NRG1 fusions (22:54) CME information and select publications